title: Salvage chemotherapy with docetaxel, ifosfamide and nedaplatin (DIN) for patients with advanced germ cell tumors: a preliminary report.
abstract: OBJECTIVE
  We investigated the efficacy and toxicity of a docetaxel, ifosfamide and nedaplatin regimen as salvage therapy for patients with advanced testicular germ cell tumor.
  
  
  METHODS
  Eleven patients with advanced germ cell tumor refractory or relapsed after cisplatin-based chemotherapy were treated using docetaxel, ifosfamide and nedaplatin. The docetaxel, ifosfamide and nedaplatin regimen comprised docetaxel (75 mg/m(2)) on Day 1, ifosfamide (2 g/m(2)) on Days 1-3 and nedaplatin (75 mg/m(2)) on Day 2 of a 3-week cycle.
  
  
  RESULTS
  Ten (91%) of the 11 patients achieved favorable responses, including complete response in one case and partial response in nine cases. Nine (81%) of the 11 patients have continued to show no evidence of disease after docetaxel, ifosfamide and nedaplatin therapy followed by subsequent surgical resection, with a median follow-up period of 52 months. One patient died of the disease 3 months after completing docetaxel, ifosfamide and nedaplatin chemotherapy. One patient was lost to follow-up with a status of alive with disease. Ten (91%) of the 11 patients developed Grade 4 leukopenia, which was managed using granulocyte colony-stimulating factor. No patients developed sensory neuropathy or renal dysfunction.
  
  
  CONCLUSIONS
  The docetaxel, ifosfamide and nedaplatin regimen was efficacious and well-tolerated as salvage chemotherapy for patients with advanced germ cell tumor.
authors.affiliation: Department of Urology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8574, Japan. shige-yamada@uro.med.tohoku.ac.jp
authors.forename: Shigeyuki
authors.initials: S
authors.lastname: Yamada
authors.forename: Hideo
authors.initials: H
authors.lastname: Saito
authors.forename: Shinya
authors.initials: S
authors.lastname: Ohara
authors.forename: Shinichi
authors.initials: S
authors.lastname: Yamashita
authors.forename: Koji
authors.initials: K
authors.lastname: Mitsuzuka
authors.forename: Shunichi
authors.initials: S
authors.lastname: Namiki
authors.forename: Minoru
authors.initials: M
authors.lastname: Miyazato
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Kaiho
authors.forename: Akihiro
authors.initials: A
authors.lastname: Ito
authors.forename: Haruo
authors.initials: H
authors.lastname: Nakagawa
authors.forename: Shigeto
authors.initials: S
authors.lastname: Ishidoya
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Arai
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000077143:Docetaxel; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy* / Q000473:pathology; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D012008:Recurrence; D016879:Salvage Therapy / Q000379:methods*; D043823:Taxoids / Q000008:administration & dosage; D013736:Testicular Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D009944:Organoplatinum Compounds; D043823:Taxoids; D000077143:Docetaxel; C053989:nedaplatin; D007069:Ifosfamide
keywords: docetaxel; germ cell tumor; ifosfamide; nedaplatin; salvage chemotherapy